ASX: MEM - Memphasys Ltd
- Matt Birney
- Mar 20
- 3 min read
Memphasys: A rare medical device that made it to all the way to commercialisation – and in a huge market!
Memphasys Managing Director Dr David Ali on 3AW, 2GB, 4BC & 6PR Bulls N' Bears Report
Listen to ASX-listed Memphasys Managing Director Dr David Ali talk to Matt Birney on the Bulls N’ Bears Report about Memphasys’ extraordinary IVF medical invention that has just passed a clinical trial with flying colours and is about to go commercial.
TO LISTEN TO THE MEMPHASYS LTD AUDIO INTERVIEW - CLICK BELOW
Amongst other things Memphasys has been developing a reproductive biotechnology device known as Felix that the company says can select and separate the most viable sperm from semen samples for use in fertility treatments such as IVF. After a long period of R&D, Memphasys has just wrapped up what looks to be a very successful clinical trial for Felix that it says will spring-board the company into commercial operations.
RADIO INTERVIEW - TRANSCRIPT
Matt Birney - Welcome to Bulls N' Bears brought to you today by reproductive biotech company Memphasys
Matt Birney - ASX code: MEM
Matt Birney - I'm Matt Birney and I'm joined now by the Managing Director of Memphasys, David Ali
Matt Birney - Hi Dave
David Ali - G'day Matt
Matt Birney - So amongst other things Memphasys has been developing a reproductive biotechnology device known as Felix that the company says can select and separate the most viable sperm from semen samples for use in fertility treatments such as IVF. For a long period of R&D, Memphasys has just wrapped up what looks to be a very successful clinical trial for Felix that it says will spring-board the company into commercial operations.
Matt Birney - Okay Dave we'll get to those trial results shortly but first how is your Felix in vitro fertilization device different to other methods out there used for IVF, what exactly does Felix do and how's it different?
David Ali - There are a few laboratory techniques out there; DGC which is Density Gradient Centrifugation and Swim-Up, however Felix is the first electrophoresis-based sperm separation system which has been designed specifically for assisted reproductive technology and I think you should know that unlike traditional sperm separation methods such as Density Gradient Centrifugation and Swim-Up, Felix actually uses a gentle electrical charge and size-exclusion membranes to rapidly and efficiently isolate the highest quality sperm for use in IVF.
Matt Birney - Okay well tell me about this clinical trial, let's not get to the results yet just tell me without getting too scientific exactly what was the trial testing for and how did you go about it?
David Ali - Well we have to test our Felix device against the current standard practice which is Density Gradient Centrifugation or Swim-Up. Our clinical trial was a phase three non-inferiority study which compared embryo utilization between the most commonly used techniques that being DGC and within the context of that trial we tested Felix against those two processes.
Matt Birney - Okay and what did you learn? What were the key outcomes?
David Ali - Well the key outcome I think was astounding. The Felix met its primary endpoint and demonstrated superior performance and when I say that, our analysis of the primary end point showed that Felix was in fact not inferior to Swim-Up which is a fantastic outcome, more importantly and we found that statistically Felix was actually superior to Density Gradient Centrifugation which is actually the most common sperm preparation technique used globally and I think that's an outstanding outcome.
Matt Birney - Can you now go commercial without any further restraints and if so where? What's the plan?
David Ali - Oh absolutely. So we're currently in the process of preparing our submission for CE Mark in Europe and that should take around six to a maximum of 12 months to achieve and once we've done that Matt, we can effectively commercialize or sell in Europe. We can then sell in Australia and move our sales into India. Having the clinical trial results it will help us greatly because we're currently already selling in Japan, where we are allowed to, but now that we've actually got the data to show that our technique is superior to currently used laboratory processes, we should be able to up our game in Japan and hopefully open up further sales.
Matt Birney - David Ali from Memphasys
Matt Birney - Thanks for joining me on Bulls N' Bears and remember we're only here to give you information, not advice, which you should of course seek independently.
Matt Birney - I'm Matt Birney and this is Bulls N' Bears.
Outro - For more public company interviews go to the money page on the 6PR, 2GB, 3AW and 4BC websites and click the public companies tab.
